Statins for millions more?

Lancet. 2014 Feb 22;383(9918):669. doi: 10.1016/S0140-6736(14)60240-3.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Atorvastatin
  • Cardiovascular Diseases / economics
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / prevention & control*
  • Cost-Benefit Analysis
  • Drug Costs
  • Heptanoic Acids / administration & dosage
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics*
  • Patient Participation
  • Practice Guidelines as Topic
  • Primary Prevention / standards
  • Pyrroles / administration & dosage
  • Risk Assessment
  • Risk Factors
  • Risk Reduction Behavior*
  • Secondary Prevention / standards
  • United Kingdom / epidemiology

Substances

  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrroles
  • Atorvastatin